fzd7

SRI 37892是一种 Fzd7抑制剂，对 Wnt β-catenin 信号传导和癌症细胞活性具有强大的活性。

F7H 是一种有效的卷曲蛋白受体 (Frizzled receptor) FZD7 拮抗剂，IC50 值为 1.25 μM。F7H 是一种有效的 FZD7 跨膜结构域 (TMD) 的配体，具有潜在的抗肿瘤和抑菌活性。

Fz7-21 ((Ac)-LPSDDLEFWCHVMY-NH2) 是一种 Frizzled 7 (FZD 7) 受体的肽抑制剂，能够选择性的与FZD7 CRD 亚类结合。它还阻断了WNT3A 介导的β-catenin 在小鼠L 细胞中的稳定作用。它对外源性WNT3A 刺激和转染WNT3A 或WNT1的HEK293细胞Wnt β-catenin 信号传导有损伤。

FZD7 antagonist 1 (peptide 34), a dFz7-21 analogue, inhibits wnt3a with an IC50 of 9.2 nM and blocks TcdB−FZD interaction by targeting FZD receptors [1].

FJ9 is a FZD7 inhibitor which disrupts protein-protein interaction between Frz7 and the PDZ domain of DVL, and induces apoptosis in melanoma cell line and non-small cell lung cancer cell line.

Fz7-21 TFA ((Ac)-LPSDDLEFWCHVMY-NH2 TFA), a peptide antagonist of Frizzled 7 (FZD 7) receptors, selectively binds to FZD7 CRD subclass. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively.